^
Association details:
| Biomarker: | MTAP deletion + KRAS G12C |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) + TNG908 (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
24P - Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model
Published date:
03/03/2022
Excerpt:
In an MTAPnull/KRASG12C-mutant lung adenocarcinoma xenograft model, combination of TNG908 and sotorasib at clinically relevant doses drove tumor regressions, which outperformed exposure-matched single agent activity for either compound, demonstrating a strong in vivo combination benefit.
